MTOR and head and neck squamous cell carcinoma: A senostatic effect of Metformin was also reported, showing its ability to modulate the profile of the senescence-associated secretory phenotype elicited by LY2835219, a CDK4/6 inhibitor in HNSCC, by inhibiting the mTOR and STAT3 pathways.